Clinical registry of dental outcomes in head and neck cancer patients (OraRad): rationale, methods, and recruitment considerations

Rajesh V Lalla, Leslie Long-Simpson, James S Hodges, Nathaniel Treister, Thomas Sollecito, Brian Schmidt, Lauren L Patton, Michael T Brennan, OraRad Study Group, Rajesh V Lalla, Leslie Long-Simpson, James S Hodges, Nathaniel Treister, Thomas Sollecito, Brian Schmidt, Lauren L Patton, Michael T Brennan, OraRad Study Group

Abstract

Background: Most head and neck (H&N) cancer patients receive high-dose external beam radiation therapy (RT), often in combination with surgery and/or chemotherapy. Unfortunately, high-dose RT has significant adverse effects on the oral and maxillofacial tissues, some of which persist for the life of the patient. However, dental management of these patients is based largely on individual and expert opinion, as few studies have followed patients prospectively to determine factors that predict adverse oral sequelae. In addition, many previous studies were conducted before wide-spread adoption of intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy. The objective of this multi-center study is to systematically evaluate the oral health of subjects for 2 years after commencement of RT, with the goal of identifying risk factors that predict adverse oral outcomes post-RT.

Methods: This is a prospective multi-center longitudinal cohort study of H&N cancer patients who receive high-dose RT with curative intent. Planned enrollment is 756 subjects at 6 primary clinical sites (and their affiliated sites) in the USA. A baseline visit is conducted prior to the beginning of RT. Follow-up visits are conducted at 6, 12, 18 and 24 months from the start of RT. The primary outcome measure is the 2-year rate of tooth loss in patients who have received at least one session of external beam RT for H&N cancer. Secondary outcome measures include the incidence of exposed intraoral bone; incidence of post-extraction complications; change in Decayed Missing and Filled Surfaces (DMFS); change in periodontal measures; change in stimulated whole salivary flow rates; change in mouth opening; topical fluoride utilization; chronic oral mucositis incidence; changes in RT-specific quality of life measures; and change in oral pain scores.

Discussion: This study will contribute to a better understanding of the dental complications experienced by these patients. It will also enable identification of risk factors associated with adverse outcomes such as tooth loss and osteoradionecrosis. These findings will support the development of evidence-based guidelines and inform the planning of future interventional studies, with the goal of advancing improvements in patient care and outcomes.

Trial registration: ClinicalTrials.gov Identifier NCT02057510 , registered 5 February 2014.

Keywords: Caries; Exposed bone; Head and neck cancer; Osteoradionecrosis; Periodontal disease; Protocol; Radiation therapy; Recruitment; Salivary flow; Tooth loss.

Figures

Fig. 1
Fig. 1
Sequence of a subject’s participation

References

    1. Pfister DG, Spencer S, Brizel DM, et al. Head and neck cancers, version 1.2015. J Natl Compr Canc Netw. 2015;13(7):847–855.
    1. Lalla RV, Brennan MT, Schubert MM. Oral Complications of Cancer Therapy. In: Yagiela J, editor. Pharmacology and Therapeutics for Dentistry. St. Louis, MO: Lippincott Williams & Wilkins; 2010.
    1. Jensen SB, Pedersen AM, Vissink A, et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer. 2010;18(8):1039–1060. doi: 10.1007/s00520-010-0827-8.
    1. Hong CH, Napenas JJ, Hodgson BD, et al. A systematic review of dental disease in patients undergoing cancer therapy. Support Care Cancer. 2010;18(8):1007–1021. doi: 10.1007/s00520-010-0873-2.
    1. Buglione M, Cavagnini R, Di Rosario F, et al. Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement. Crit Rev Oncol Hematol. 2016;102:47–54. doi: 10.1016/j.critrevonc.2016.03.012.
    1. Buglione M, Cavagnini R, Di Rosario F, et al. Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement. Crit Rev Oncol Hematol. 2016;97:131–142. doi: 10.1016/j.critrevonc.2015.08.010.
    1. Brennan MT, Woo SB, Lockhart PB. Dental treatment planning and management in the patient who has cancer. Dent Clin North Am. 2008;52(1):19–37. doi: 10.1016/j.cden.2007.10.003.
    1. Bruins HH, Jolly DE, Koole R. Preradiation dental extraction decisions in patients with head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88(4):406–412. doi: 10.1016/S1079-2104(99)70053-3.
    1. Ramfjord SP. Indices for prevalence and incidence of periodontal disease. J Periodontol. 1959;30:51–59. doi: 10.1902/jop.1959.30.1.51.
    1. World Health Organization . Handbook for reporting results of cancer treatment. Geneva: World Health Organization; 1979.
    1. Connelly ST, Schmidt BL. Evaluation of pain in patients with oral squamous cell carcinoma. J Pain. 2004;5(9):505–510. doi: 10.1016/j.jpain.2004.09.002.
    1. European Organisation for Research and Treatment of Cancer. EORTC QLQ - H&N35. [Internet document] 2009 [cited 2011 9 November]; Available from: .
    1. Peterson DE, Doerr W, Hovan A, et al. Osteoradionecrosis in cancer patients: the evidence base for treatment-dependent frequency, current management strategies, and future studies. Support Care Cancer. 2010;18(8):1089–1098. doi: 10.1007/s00520-010-0898-6.
    1. Gomez DR, Estilo CL, Wolden SL, et al. Correlation of osteoradionecrosis and dental events with dosimetric parameters in intensity-modulated radiation therapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011;81(4):e207–e213. doi: 10.1016/j.ijrobp.2011.02.003.
    1. MacCallum RC, Widaman KF, Zhang S, Hong S. Sample size in factor analysis. Psychol Methods. 1999;4:84–99. doi: 10.1037/1082-989X.4.1.84.
    1. Unger JM, Hershman DL, Albain KS, et al. Patient income level and cancer clinical trial participation. J Clin Oncol. 2013;31(5):536–542. doi: 10.1200/JCO.2012.45.4553.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere